Samsung Bioepis is reportedly seeking regulatory approval to sell a biosimilar version of Humira® (adalimumab) in South Korea. Also, in July 2016, Samsung Bioepis reported that the EMA had accepted its Marketing Authorization Application for SB5, an adalimumab biosimilar.

As we recently reported, Samsung Bioepis already has approved biosimilar applications for etanercept and infliximab products in a number of jurisdictions.

Stay tuned to Big Molecule Watch for more industry updates.